Mestag was founded in 2020 to develop impactful therapies for patients by targeting activated fibroblast populations and their role in influencing the immune system in disease.
— Sachs Associates (@SachsAssociates) February 7, 2022
e-Meet @Mestagtx at #Sachs_ELSF
More info @ https://t.co/b7zJA2j8ns pic.twitter.com/XXAFGmHC7y